PMDA drug package insert
ドキソルビシン塩酸塩注射液10mg「サンド」
PMDA Prescription drug · サンド株式会社 · package insert Jul 27, 2023
Key facts
| Brand names | ドキソルビシン塩酸塩注射液10mg「サンド」, ドキソルビシン塩酸塩注射液50mg「サンド」 |
|---|---|
| Nonproprietary names | ドキソルビシン塩酸塩 |
| Companies | 製造販売／サンド株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤 |
| Therapeutic category codes | 874235 |
| YJ codes | 4235402A2021, 4235402A3028 |
| Approval numbers | 22200AMX00189, 22200AMX00190 |
| Package insert edition | 第1版 |
| Package insert date | Jul 27, 2023 |
| PMDA document key | 270428_4235402A2021_1 |
| PMDA company code | 270428 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: